These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 19224343)
1. Manufacturing nanosized fenofibrate by salt assisted milling. Mochalin VN; Sagar A; Gour S; Gogotsi Y Pharm Res; 2009 Jun; 26(6):1365-70. PubMed ID: 19224343 [TBL] [Abstract][Full Text] [Related]
2. Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals. Zuo B; Sun Y; Li H; Liu X; Zhai Y; Sun J; He Z Int J Pharm; 2013 Oct; 455(1-2):267-75. PubMed ID: 23876497 [TBL] [Abstract][Full Text] [Related]
3. Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate. Sironi D; Rosenberg J; Bauer-Brandl A; Brandl M Eur J Pharm Sci; 2017 Jan; 96():20-27. PubMed ID: 27597143 [TBL] [Abstract][Full Text] [Related]
5. Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering. Wang P; Luo Q; Miao Y; Ying L; He H; Cai C; Tang X Drug Dev Ind Pharm; 2012 Nov; 38(11):1344-53. PubMed ID: 22283480 [TBL] [Abstract][Full Text] [Related]
6. Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles. Juenemann D; Jantratid E; Wagner C; Reppas C; Vertzoni M; Dressman JB Eur J Pharm Biopharm; 2011 Feb; 77(2):257-64. PubMed ID: 21074611 [TBL] [Abstract][Full Text] [Related]
7. Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach. Patil H; Feng X; Ye X; Majumdar S; Repka MA AAPS J; 2015 Jan; 17(1):194-205. PubMed ID: 25344439 [TBL] [Abstract][Full Text] [Related]
8. Stabilization of fenofibrate in low molecular weight hydroxypropylcellulose matrices produced by hot-melt extrusion. Deng W; Majumdar S; Singh A; Shah S; Mohammed NN; Jo S; Pinto E; Tewari D; Durig T; Repka MA Drug Dev Ind Pharm; 2013 Feb; 39(2):290-8. PubMed ID: 22524504 [TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. Hens B; Brouwers J; Corsetti M; Augustijns P Eur J Pharm Sci; 2015 Sep; 77():40-7. PubMed ID: 26004010 [TBL] [Abstract][Full Text] [Related]
10. Mesoporous silica-based dosage forms improve release characteristics of poorly soluble drugs: case example fenofibrate. Dressman JB; Herbert E; Wieber A; Birk G; Saal C; Lubda D J Pharm Pharmacol; 2016 May; 68(5):634-45. PubMed ID: 26255860 [TBL] [Abstract][Full Text] [Related]
11. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability. Ige PP; Baria RK; Gattani SG Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990 [TBL] [Abstract][Full Text] [Related]
12. Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying. Hu J; Ng WK; Dong Y; Shen S; Tan RB Int J Pharm; 2011 Feb; 404(1-2):198-204. PubMed ID: 21056643 [TBL] [Abstract][Full Text] [Related]
13. Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability. Zhang L; Chai G; Zeng X; He H; Xu H; Tang X Drug Dev Ind Pharm; 2010 Sep; 36(9):1054-63. PubMed ID: 20818965 [TBL] [Abstract][Full Text] [Related]
14. Development and characterization of dilutable self-microemulsifying premicroemulsion systems (SMEPMS) as templates for preparation of nanosized particulates. Lin SF; Chen YC; Ho HO; Huang WY; Sheu MT; Liu DZ Int J Nanomedicine; 2013; 8():3455-66. PubMed ID: 24049445 [TBL] [Abstract][Full Text] [Related]
15. Micronization of drugs using supercritical carbon dioxide. Kerc J; Srcic S; Knez Z; Sencar-Bozic P Int J Pharm; 1999 May; 182(1):33-9. PubMed ID: 10332072 [TBL] [Abstract][Full Text] [Related]
16. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations. Pestieau A; Krier F; Brouwers A; Streel B; Evrard B Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683 [TBL] [Abstract][Full Text] [Related]
17. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Sanganwar GP; Gupta RB Int J Pharm; 2008 Aug; 360(1-2):213-8. PubMed ID: 18550302 [TBL] [Abstract][Full Text] [Related]
18. Designing starch-based fenofibrate formulations using the melting method. Sohn JS; Choi YE; Choi JS Int J Biol Macromol; 2024 Jun; 272(Pt 2):132903. PubMed ID: 38848840 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of different in vitro dissolution tests based on level A in vitro-in vivo correlations for fenofibrate self-emulsifying lipid-based formulations. Pestieau A; Lebrun S; Cahay B; Brouwers A; Streel B; Cardot JM; Evrard B Eur J Pharm Biopharm; 2017 Mar; 112():18-29. PubMed ID: 27865930 [No Abstract] [Full Text] [Related]
20. The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate. Do TT; Van Speybroeck M; Mols R; Annaert P; Martens J; Van Humbeeck J; Vermant J; Augustijns P; Van den Mooter G Int J Pharm; 2011 Jul; 414(1-2):118-24. PubMed ID: 21596119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]